Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose There are no reliable biomarkers to guide treatment for patients with borderline resectable pancreatic cancer (BRPC) in the neoadjuvant setting. We used plasma circulating tumor DNA (ctDNA) sequencing to search biomarkers for patients with BRPC receiving neoadjuvant mFOLFIRINOX in our phase 2 clinical trial (NCT02749136). Materials and Methods Among the 44 patients enrolled in the trial, patients with plasma ctDNA sequencing at baseline or post-operation were included in this analysis. Plasma cell-free DNA isolation and sequencing were performed using the Guardant 360 assay. Detection of genomic alterations, including DNA damage repair (DDR) genes, were examined for correlations with survival. Results Among the 44 patients, 28 patients had ctDNA sequencing data qualified for the analysis and were included in this study. Among the 25 patients with baseline plasma ctDNA data, 10 patients (40%) had alterations of DDR genes detected at baseline, inclu-ding ATM, BRCA1, BRCA2 and MLH1, and showed significantly better progression-free survival than those without such DDR gene alterations detected (median, 26.6 vs. 13.5 months; log-rank p=0.004). Patients with somatic KRAS mutations detected at baseline (n=6) had significantly worse overall survival (median, 8.5 months vs. not applicable; log-rank p=0.003) than those without. Among 13 patients with post-operative plasma ctDNA data, eight patients (61.5%) had detectable somatic alterations. Conclusion Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of pati-ents with borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.
Abstract
Purpose There are no reliable biomarkers to guide treatment for patients with borderline resectable pancreatic cancer (BRPC) in the neoadjuvant setting. We used plasma circulating tumor DNA (ctDNA) sequencing to search biomarkers for patients with BRPC receiving neoadjuvant mFOLFIRINOX in our phase 2 clinical trial (NCT02749136). Materials and Methods Among the 44 patients enrolled in the trial, patients with plasma ctDNA sequencing at baseline or post-operation were included in this analysis. Plasma cell-free DNA isolation and sequencing were performed using the Guardant 360 assay. Detection of genomic alterations, including DNA damage repair (DDR) genes, were examined for correlations with survival. Results Among the 44 patients, 28 patients had ctDNA sequencing data qualified for the analysis and were included in this study. Among the 25 patients with baseline plasma ctDNA data, 10 patients (40%) had alterations of DDR genes detected at baseline, inclu-ding ATM, BRCA1, BRCA2 and MLH1, and showed significantly better progression-free survival than those without such DDR gene alterations detected (median, 26.6 vs. 13.5 months; log-rank p=0.004). Patients with somatic KRAS mutations detected at baseline (n=6) had significantly worse overall survival (median, 8.5 months vs. not applicable; log-rank p=0.003) than those without. Among 13 patients with post-operative plasma ctDNA data, eight patients (61.5%) had detectable somatic alterations. Conclusion Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of pati-ents with borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.
참고문헌 (30)
- Mizrahi JD, "Pancreatic cancer", Lancet, 395, pp.2008~2020 (2020)
- Al-Hawary MM, "Pancreatic ductal adenocarcinoma radiology reporting template : consensus statement of the society of abdominal radiology and the american pancreatic association", Gastroenterology, 146, pp.291~304 (2014)
- Gillen S, "Preoperative", neoadjuvant therapy in pancreatic cancer : a systematic review and meta-analysis of response and resection percentages, 2010, pp.7, e1000267~
- "Pancreatic adenocarcinoma (version 1.2021)" (2021)[URL]
- Yoo C, "Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma : a Phase 2 study for clinical and biomarker analysis", Br J Cancer, 123, pp.362~368 (2020)
- Hyung J, "Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma : a narrative review", Chin Clin Oncol, 11, pp.20~ (2022)
- Wan JC, "Liquid biopsies come of age : towards imp-lementation of circulating tumour DNA", Nat Rev Cancer, 17, pp.223~238 (2017)
- Russano M, "Liquid biopsy and tumor heterogeneity in metastatic solid tumors : the potentiality of blood samples", J Exp Clin Cancer Res, 39, pp.95~ (2020)
- Faulkner LG, "The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer : a systematic review and meta-analysis", Br J Cancer, 128, pp.297~309 (2023)
- Magbanua MJ, "Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival", Ann Oncol, 32, pp.229~239 (2021)
- Bernard V, "Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer", Gastroenterology, 156, pp.108~118 (2019)
- Bhangu JS, "Circulating free methylated tumor DNA markers for sensitive assessment of tumor burden and early response monitoring in patients receiving systemic chemotherapy for colorectal cancer liver metastasis", Ann Surg, 268, pp.894~902 (2018)
- Wattenberg MM, "Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation", Br J Cancer, 122, pp.333~339 (2020)
- Golan T, "Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers", Br J Cancer, 111, pp.1132~1138 (2014)
- Huang R, "DNA damage repair : historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy", Signal Transduct Target Ther, 6, pp.254~ (2021)
- Cancer Genome Atlas Research Network, "Integrated genomic characterization of pancreatic ductal adenocarcinoma", Cancer Cell, 32, pp.185~203 (2017)
- Cerami E, "The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)
- Gao J, "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal", Sci Signal, 6, pp.pl1~ (2013)
- Nakano Y, "KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker : a retrospective study", Br J Cancer, 118, pp.662~669 (2018)
- Lord CJ, "The DNA damage response and cancer therapy", Nature, 481, pp.287~294 (2012)
- Dilruba S, "Platinum-based drugs : past, present and future", Cancer Chemother Pharmacol, 77, pp.1103~1124 (2016)
- Plimack ER, "Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder Cancer", Eur Urol, 68, pp.959~967 (2015)
- Mota JM, "Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations", JCO Precis Oncol, 4, pp.355~366 (2020)
- Sehdev A, "Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX", Clin Cancer Res, 24, pp.6204~6211 (2018)
- Pishvaian MJ, "Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways : results from the know your tumor program", JCO Precis Oncol, 3, pp.1~10 (2019)
- Luo J, "KRAS mutation in pancreatic cancer", Semin Oncol, 48, pp.10~18 (2021)
- Guo S, "Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients", Br J Cancer, 122, pp.857~867 (2020)
- Earl J, "Circulating tumor cells(Ctc)and kras mutant circulating free Dna(cfdna)detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer", BMC Cancer, 15, pp.797~ (2015)
- Guven DC, "A systematic review and meta-analysis of the association between circulating tumor DNA(ctDNA)and prognosis in pancreatic cancer", Crit Rev Oncol Hematol, 168, pp.103528~ (2021)
- Chen L, "Prognostic value of circulating cell-free DNA in patients with pancreatic cancer : a systemic review and meta-analysis", Gene, 679, pp.328~334 (2018)